LONDON--(BUSINESS WIRE)--Regulatory News:
Stallergenes Greer plc (Paris:STAGR) has announced the appointment of Michele Antonelli as Executive Vice President, Head of International Operations on 9 November 2015.
Michele has more than 20 years’ extensive international experience in the biopharmaceutical industry. For the past 7 years, Michele has worked at UCB, where he has held roles of various responsibility and scope, most recently holding the position of Executive Vice President and Head of lmmunology Europe, overseeing commercial, medical and market access activities in the region. Michele gained extensive experience in setting up and managing commercial and technical operations in Europe, the United States, Latin America, Israel and Asia. Prior to joining UCB, Michele spent 16 years at Merck Serono, ultimately in the role of Senior Vice President and Global Head of Biotech Manufacturing and Process Development in Geneva.
Christian Chavy, Head of Commercial Operations Europe & ROW of Stallergenes Greer, said: “We are delighted to welcome Michele Antonelli. His leadership experience within successful biopharmaceutical companies, combined with his extensive knowledge of the key markets in which Stallergenes Greer operates, will support our company in its future development and in fully capitalizing on our value creation strategy around the world.”
ABOUT STALLERGENES GREER PLC
Headquartered in London (UK), Stallergenes Greer plc is a global company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).
Name: Stallergenes Greer
ISIN: GB00BZ21RF93 1 - Ticker: STAGR
ICB classification: 4577
Market: Euronext Paris regulated market
Additional information is available at http://www.stallergenesgreer.com